Cargando…

Safety and Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Children Aged 2–5 Years in the United States

In a phase 4, randomized, placebo-controlled, double-blind, multicenter study, to assess the safety and immunogenicity of live, attenuated cholera vaccine PXVX0200 in children aged 2–5 years in the United States, 172 volunteers were randomized 6:1 to receive a single dose of 1 × 10(9) colony forming...

Descripción completa

Detalles Bibliográficos
Autores principales:	McCarty, James M., Cassie, David, Bedell, Lisa, Lock, Michael D., Bennett, Sean
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Tropical Medicine and Hygiene 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941807/ https://www.ncbi.nlm.nih.gov/pubmed/33319739 http://dx.doi.org/10.4269/ajtmh.20-0917

Ejemplares similares

Long-Term Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Adolescents Aged 12–17 Years in the United States
por: McCarty, James M., et al.
Publicado: (2021)

Safety and Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Children and Adolescents Aged 6–17 Years
por: McCarty, James M., et al.
Publicado: (2020)

CVD 103-HgR live, attenuated cholera vaccine strain viability in drinking waters from the US and Europe
por: Duffin, R. Paul, et al.
Publicado: (2021)

Age-Dependent Association among Helicobacter pylori Infection, Serum Pepsinogen Levels and Immune Response of Children to Live Oral Cholera Vaccine CVD 103-HgR
por: Muhsen, Khitam, et al.
Publicado: (2014)

Pre-existing Helicobacter pylori serum IgG enhances the vibriocidal antibody response to CVD 103-HgR live oral cholera vaccine in Malian adults
por: Muhsen, Khitam, et al.
Publicado: (2020)

Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial Comparing the Reactogenicity and Immunogenicity of a Single Standard Dose to Those of a High Dose of CVD 103-HgR Live Attenuated Oral Cholera Vaccine, with Shanchol Inactivated Oral Vaccine as an Open-Label Immunologic Comparator
por: Sow, Samba O., et al.
Publicado: (2017)

Anti-O-specific polysaccharide (OSP) immune responses following vaccination with oral cholera vaccine CVD 103-HgR correlate with protection against cholera after infection with wild-type Vibrio cholerae O1 El Tor Inaba in North American volunteers
por: Islam, Kamrul, et al.
Publicado: (2018)

The HGR motif is the antiangiogenic determinant of vasoinhibin: implications for a therapeutic orally active oligopeptide
por: Robles, Juan Pablo, et al.
Publicado: (2021)

HGR-ViT: Hand Gesture Recognition with Vision Transformer
por: Tan, Chun Keat, et al.
Publicado: (2023)

Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine
por: Levine, Myron M
Publicado: (2010)

Importancia perinatal del estudio de la placenta en H.G.R. no.36
por: Cortés Vásquez, F. Jose Luis
Publicado: (1992)

Immunogenicity and protective efficacy of a live, oral cholera vaccine formulation stored outside-the-cold-chain for 140 days
por: Xian, Tew Hui, et al.
Publicado: (2020)

Assessment of the influence of ABO blood groups on oral cholera vaccine immunogenicity in a cholera endemic area in Zambia
por: Chisenga, Caroline C., et al.
Publicado: (2023)

Effect of HIV status and retinol on immunogenicity to oral cholera vaccine in adult population living in an endemic area of Lukanga Swamps, Zambia
por: Luchen, Charlie Chaluma, et al.
Publicado: (2021)

Preclinical Bioavailability Assessment of a Poorly Water-Soluble Drug, HGR4113, Using a Stable Isotope Tracer
por: Ha, Eun Ji, et al.
Publicado: (2023)

HGR7: 7th International Conference on the History of General Relativity: Einstein and the Changing World Views of Physics, 1905-2005
Publicado: (2005)

Safety and Immunogenicity of a Live Oral Recombinant Cholera Vaccine VA1.4: A Randomized, Placebo Controlled Trial in Healthy Adults in a Cholera Endemic Area in Kolkata, India
por: Kanungo, Suman, et al.
Publicado: (2014)

Safety and Immunogenicity Assessment of an Oral Cholera Vaccine through Phase I Clinical Trial in Korea
por: Baik, Young Ok, et al.
Publicado: (2014)

Immunogenicity of a bivalent killed thimerosal-free oral cholera vaccine, Euvichol, in an animal model
por: Lee, Eun Young, et al.
Publicado: (2018)

Frecuencias de enfermedades oportunistas en pacientes con VIH positivo en el HGR – 6 IMSS, ciudad Madero, Tamaulipas
por: Hernández Pérez, Eva Alicia
Publicado: (1998)

Frecuencia de enfermedades oportunistas en pacientes con VIH positivo en el HGR-6 IMSS, ciudad Madero, Tamaulipas /
por: Hernández Pérez, Eva Alicia
Publicado: (1998)

Comorbidité COVID-19 et maladies chroniques à l'Hôpital général de référence (HGR) de Niamey au Niger
por: Diawara, A., et al.
Publicado: (2022)

Oral cholera vaccine in cholera prevention and control, Malawi
por: M’bangombe, Maurice, et al.
Publicado: (2018)

CD103 in the development of experimental asthma
por: Blanchet, Marie-Renee, et al.
Publicado: (2010)

Immunogenicity and waning immunity from the oral cholera vaccine (Shanchol(™)) in adults residing in Lukanga Swamps of Zambia
por: Ng′ombe, Harriet, et al.
Publicado: (2022)

An Age-stratified, Randomized Immunogenicity Trial of Killed Oral Cholera Vaccine with Delayed Second Dose in Cameroon
por: Ateudjieu, Jérôme, et al.
Publicado: (2022)

Scalable production and immunogenicity of a cholera conjugate vaccine
por: Jeon, Suhi, et al.
Publicado: (2021)

Identification of Immunogenic Antigens of Naegleria fowleri Adjuvanted by Cholera Toxin
por: Rojas-Hernández, Saúl, et al.
Publicado: (2020)

Symphony No. 103/
por: Haydn, Joseph

Immunogenicity and inflammatory properties of respiratory syncytial virus attachment G protein in cotton rats
por: Martinez, Margaret E., et al.
Publicado: (2021)

Electromagnetic properties of low-lying states in neutron-deficient Hg isotopes: Coulomb excitation of $^{182}$Hg, $^{184}$Hg, $^{186}$Hg and $^{188}$Hg
por: Wrzosek-Lipska, K, et al.
Publicado: (2019)

Evaluating Cardiovascular Disease (CVD) risk scores for participants with known CVD and non-CVD in a multiracial/ethnic Caribbean sample
por: Hosein, Amalia, et al.
Publicado: (2020)

Immunogenicity of a Killed Bivalent (O1 and O139) Whole Cell Oral Cholera Vaccine, Shanchol, in Haiti
por: Charles, Richelle C., et al.
Publicado: (2014)

Cholera
por: Bennett, Vivian B.
Publicado: (1917)

The alpha decay of $^{179}$Hg and $^{178}$Hg
por: Hansen, P G, et al.
Publicado: (1971)

The alpha decay of $^{179}Hg$ and $ ^{178}Hg$
por: Hansen, P G, et al.
Publicado: (1971)

CVD and Oxidative Stress
por: Cervantes Gracia, Karla, et al.
Publicado: (2017)

LncRNA MIR503HG inhibits cell migration and invasion via miR‐103/OLFM4 axis in triple negative breast cancer
por: Fu, Jia, et al.
Publicado: (2019)

A Randomized, Placebo-Controlled Trial Evaluating Safety and Immunogenicity of the Killed, Bivalent, Whole-Cell Oral Cholera Vaccine in Ethiopia
por: Desai, Sachin N., et al.
Publicado: (2015)

Immunogenicity and Protection From a Single Dose of Internationally Available Killed Oral Cholera Vaccine: A Systematic Review and Metaanalysis
por: Lopez, Anna Lena, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vc2fhficiqjnkf8124ovqclhun